Subsequent Event	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
Subsequent Event	9. Subsequent Events At-the-Market-Offering Subsequent to June 30, 2025, from July 1, 2025, through August 12, 2025, the Company raised aggregate net proceeds of approximately $108.7 million under the ATM sales agreement. Strategic Pipeline Prioritization On August 12, 2025, the Company announced a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits. The Company estimates that the workforce reduction will be substantially complete in the third quarter of 2025 and that the majority of the related charges will be recognized in the Company’s financial results of operations for the third quarter of 2025. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ from these estimates.

Subsequent Event

6 Months Ended

Jun. 30, 2025

9. Subsequent Events

At-the-Market-Offering

Subsequent to June 30, 2025, from July 1, 2025, through August 12, 2025, the Company raised aggregate net proceeds of approximately $108.7 million under the ATM sales agreement.

Strategic Pipeline Prioritization

On August 12, 2025, the Company announced a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits. The Company estimates that the workforce reduction will be substantially complete in the third quarter of 2025 and that the majority of the related charges will be recognized in the Company’s financial results of operations for the third quarter of 2025. The estimate of costs that the Company expects to incur and the timing thereof are subject to a number of assumptions, and actual results may differ from these estimates.

Oric Pharmaceuticals, Inc. 10-Q